Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)

Abstract

Glucocorticosteroids (GCS) are used on a daily basis to reduce airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). This treatment is usually escalated during acute disease exacerbations, events often associated with virus infections. We examined the impact of GCS on anti-viral defences and virus replication and assessed supplementary interferon (IFN) treatment. Here, we report that treatment of primary human airway cells in vitro with GCS prior to rhinovirus (RV) or influenza A virus (IAV) infection significantly reduces the expression of innate anti-viral genes and increases viral replication. Mice given intranasal treatment with GCS prior to IAV infection developed more severe disease associated with amplified virus replication and elevated inflammation in the airways. Adjuvant IFN treatment markedly reduced GCS-amplified infections in human airway cells and in mouse lung. This study demonstrates that GCS cause an extrinsic compromise in anti-viral defences, enhancing respiratory virus infections and provides a rationale for adjuvant IFN treatment.
Original languageEnglish
Pages (from-to)1 - 11
Number of pages11
JournalScientific Reports
Volume4
Issue numberArt. ID: 7176
DOIs
Publication statusPublished - 2014

Cite this

@article{96c9b36bb1384088bffe57c448f53548,
title = "Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon",
abstract = "Glucocorticosteroids (GCS) are used on a daily basis to reduce airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). This treatment is usually escalated during acute disease exacerbations, events often associated with virus infections. We examined the impact of GCS on anti-viral defences and virus replication and assessed supplementary interferon (IFN) treatment. Here, we report that treatment of primary human airway cells in vitro with GCS prior to rhinovirus (RV) or influenza A virus (IAV) infection significantly reduces the expression of innate anti-viral genes and increases viral replication. Mice given intranasal treatment with GCS prior to IAV infection developed more severe disease associated with amplified virus replication and elevated inflammation in the airways. Adjuvant IFN treatment markedly reduced GCS-amplified infections in human airway cells and in mouse lung. This study demonstrates that GCS cause an extrinsic compromise in anti-viral defences, enhancing respiratory virus infections and provides a rationale for adjuvant IFN treatment.",
author = "Belinda Thomas and Porritt, {Rebecca A} and Hertzog, {Paul John} and Bardin, {Philip G} and Michelle Tate",
year = "2014",
doi = "10.1038/srep07176",
language = "English",
volume = "4",
pages = "1 -- 11",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "Art. ID: 7176",

}

Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. / Thomas, Belinda; Porritt, Rebecca A; Hertzog, Paul John; Bardin, Philip G; Tate, Michelle.

In: Scientific Reports, Vol. 4, No. Art. ID: 7176, 2014, p. 1 - 11.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon

AU - Thomas, Belinda

AU - Porritt, Rebecca A

AU - Hertzog, Paul John

AU - Bardin, Philip G

AU - Tate, Michelle

PY - 2014

Y1 - 2014

N2 - Glucocorticosteroids (GCS) are used on a daily basis to reduce airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). This treatment is usually escalated during acute disease exacerbations, events often associated with virus infections. We examined the impact of GCS on anti-viral defences and virus replication and assessed supplementary interferon (IFN) treatment. Here, we report that treatment of primary human airway cells in vitro with GCS prior to rhinovirus (RV) or influenza A virus (IAV) infection significantly reduces the expression of innate anti-viral genes and increases viral replication. Mice given intranasal treatment with GCS prior to IAV infection developed more severe disease associated with amplified virus replication and elevated inflammation in the airways. Adjuvant IFN treatment markedly reduced GCS-amplified infections in human airway cells and in mouse lung. This study demonstrates that GCS cause an extrinsic compromise in anti-viral defences, enhancing respiratory virus infections and provides a rationale for adjuvant IFN treatment.

AB - Glucocorticosteroids (GCS) are used on a daily basis to reduce airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). This treatment is usually escalated during acute disease exacerbations, events often associated with virus infections. We examined the impact of GCS on anti-viral defences and virus replication and assessed supplementary interferon (IFN) treatment. Here, we report that treatment of primary human airway cells in vitro with GCS prior to rhinovirus (RV) or influenza A virus (IAV) infection significantly reduces the expression of innate anti-viral genes and increases viral replication. Mice given intranasal treatment with GCS prior to IAV infection developed more severe disease associated with amplified virus replication and elevated inflammation in the airways. Adjuvant IFN treatment markedly reduced GCS-amplified infections in human airway cells and in mouse lung. This study demonstrates that GCS cause an extrinsic compromise in anti-viral defences, enhancing respiratory virus infections and provides a rationale for adjuvant IFN treatment.

UR - http://www.nature.com/srep/2014/141124/srep07176/pdf/srep07176.pdf

U2 - 10.1038/srep07176

DO - 10.1038/srep07176

M3 - Article

VL - 4

SP - 1

EP - 11

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - Art. ID: 7176

ER -